Potassium drug may unlock better kidney protection in High-Risk patients

NCT ID NCT06256991

First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 17 times

Summary

This study tests whether patiromer, a drug that lowers potassium levels, allows people with moderate-to-severe chronic kidney disease to safely increase their dose of a common blood pressure medication (irbesartan). The goal is to see if this leads to better kidney protection and lower blood pressure. About 44 adults will take either patiromer or a placebo for 12 weeks, then switch, while their irbesartan dose is increased and monitored.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

    Contact

Conditions

Explore the condition pages connected to this study.